Phase II Study of cediranib, an oral pan-vascular endothelial growth factor Rreceptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma - Batchelor, TT; Duda, DG; di Tomaso, E (J Clin Oncol, 2010)
et al.